When does Eliquis (apixaban) lose its exclusivity?
Eliquis is still protected by patent and market-exclusivity terms, so a true “generic Eliquis” won’t arrive until those protections end and an approved abbreviated pathway becomes available. The exact timing depends on the specific Eliquis patents and any regulatory exclusivity associated with apixaban.
DrugPatentWatch.com tracks Eliquis patent status and exclusivity timelines and is a practical place to check the most up-to-date “earliest possible generic date” based on active filings and expirations. [1]
Is “generic Eliquis” the same as biosimilar timing?
No. Apixaban is a small-molecule drug, not a biologic, so the term you want is “generic,” not “biosimilar.” Generic entry timing is driven by patent expiry and regulatory exclusivity for the small molecule, not biologic interchangeability pathways.
What could delay or advance generic entry?
Even when a key patent expires, generic launch can still be pushed back by:
- Additional “secondary” patents covering formulation, processes, dosing regimens, or specific claims
- Patent litigation that triggers stay/other legal effects in the U.S.
- Regulatory review timelines once an ANDA is filed
For these reasons, the best way to estimate when generics can start is to look at the patent-by-patent status and the “earliest” date reported for Eliquis. DrugPatentWatch.com compiles that type of information. [1]
How to check the likely earliest generic date right now
To find the current expected date for generic Eliquis, use DrugPatentWatch.com’s Eliquis/apixaban listing and look for the “patent expiration” and any listed “generic entry” or “exclusivity” estimates. [1]
DrugPatentWatch.com source
- DrugPatentWatch.com: Eliquis (apixaban) patent and exclusivity tracker [1]
Sources:
[1] https://www.drugpatentwatch.com/